Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:•           The impact of COVID-19 on CLL treatment decisions•           The use of anti-CD20 antibodies in combination with BTK inhibitors•           Considerations when recommending BTK inhibitors•           MRD testing in patients with CLL•           The potential impact of targeted therapies on when to start treatmentPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets: https://bit.ly/3hATX0L    

There are no comments yet.

Please log in to write the first comment.